Timothy Pluard

home / authors / timothy-pluard

Articles

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

Lowell Hart;Seock-Ah Im;Sara M. Tolaney, MD, MPH;Mario Campone;Timothy Pluard;Berta Sousa;Gilles Freyer;Thomas Decker;Kevin Kalinsky, MD, MS;Astrid Thuerigen;Melissa Gao;Huilin Hu;Sherko Kümmel
August 9th 2024
15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib

15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib

Emily J. Gallagher;Heather Moore;Mario E. Lacouture, MD;Susan F. Dent;Azeez Farooki, MD;Marcus D. Goncalves;Claudine Isaacs, MD;Abigail Johnston;Dejan Juric;Zoe Quandt;Laura Spring;Brian Berman;Melanie Decker;Gabriel N. Hortobagyi, MD, FACP;Benjamin H. Kaffenberger;Bernice Y. Kwong;Timothy Pluard;Ruta Rao, MD;Lee Schwartzberg, MD, FACP;Michael S. Broder
April 28th 2023

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Breast Induration in 42-Year-Old Patient
Published: April 12th 2016 | Updated: November 23rd 2024
Breast Induration in 42-Year-Old Patient
Neutropenia and Abdominal Pain in a 30-Year-Old Patient
Published: May 1st 2015 | Updated: November 23rd 2024
Neutropenia and Abdominal Pain in a 30-Year-Old Patient
A 22-Year-Old Woman With Pain, Tenderness and Swelling in the Breast
Published: August 19th 2019 | Updated: November 23rd 2024
A 22-Year-Old Woman With Pain, Tenderness and Swelling in the Breast